QUOTED. 2 April 2021. Rebecca Kelly Slaughter.
The US Federal Trade Commission is trying to stop Illumina’s planned acquisition of Grail, because it could reduce patients’ access to multi-cancer screening tests. See what FTC chairwoman Rebecca Kelly Slaughter said about it here.
"[Multi-cancer early detection] is a game changer for cancer patients and their loved ones. If this acquisition is consummated, it would likely reduce innovation in this critical area of health care, diminish the quality of [these] tests, and make them more expensive.” – Rebecca Kelly Slaughter, chairwoman, FTC
- Find out more: US Government Opposes Proposed Illumina/Grail Merger
Click here for a free trial of Medtech Insight